Intensity Therapeutics, Inc. (INTS) Reports In-Line Q3 EPS

Intensity Therapeutics, Inc. (NASDAQ: INTS) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Intensity Therapeutics, Inc. (INTS) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c